Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hyaluronidase/pertuzumab/trastuzumab - Roche

Next Previous
Drug Profile

Hyaluronidase/pertuzumab/trastuzumab - Roche

Alternative Names: Herceptin/perjeta; Perjeta/herceptin; Pertuzumab FDC SC; Pertuzumab/trastuzumab; Pertuzumab/trastuzumab/hyaluronidase-zzxf; Pertuzumab/trastuzumab/vorhyaluronidase alfa; PH FDC SC; Phesgo; Phesgo OBI; RG-6264; Trastuzumab/pertuzumab

Latest Information Update: 14 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Medica Scientia Innovation Research; Merck & Co; Roche; Seagen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; HER2 positive breast cancer
  • Phase II Solid tumours

Most Recent Events

  • 30 Apr 2025 European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion for Hyaluronidase/pertuzumab/trastuzumab in European Union
  • 22 Jul 2024 Phase-II clinical trials in HER2-positive-breast-cancer (Inoperable/Unresectable, Recurrent, Metastatic disease, Combination therapy) in Spain (SC) (NCT06172127)
  • 27 Feb 2024 Genentech completes a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO) (NCT04632992)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top